Healthy, late preterm infants treated with anti-RSV monoclonal antibody during an RSV season had 61% fewer days of wheezing during the first year of life than controls.
Severe respiratory syncytial virus (RSV) bronchiolitis is associated with subsequent wheezing and childhood asthma, but the pathogenesis is poorly understood. To assess the role of previous RSV infection in wheezing during the first year of life, researchers in the Netherlands randomized 429 healthy, late preterm infants (33 to 35 weeks' gestation) to receive monthly injections of either the monoclonal antibody palivizumab or placebo during the RSV season.
Parents, who were blinded to whether their children received antibody or placebo, were asked to keep a log of their infants' respiratory tract illness (including wheeze) for the first year of life and to obtain nasopharyngeal swabs specimens if illness lasted more than 1 day. Swabs were an…
Reviewing Author
DisclosuresGrant/Research SupportNIH Institutional Clinical and Translational Science Award; Agency for Healthcare Research and Quality National Center for Pediatric Practice Based Research Learning; Patient-Centered Outcomes Research Institute
Editorial BoardsCurrent Problems in Pediatric Adolescent Healthcare
Leadership Positions in Professional Societies College of Physicians of Philadelphia (Board of Trustees)
DisclosuresGrant/Research SupportNIH Institutional Clinical and Translational Science Award; Agency for Healthcare Research and Quality National Center for Pediatric Practice Based Research Learning; Patient-Centered Outcomes Research Institute
Editorial BoardsCurrent Problems in Pediatric Adolescent Healthcare
Leadership Positions in Professional Societies College of Physicians of Philadelphia (Board of Trustees)